AXSOME THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
AXSOME THERAPEUTICS, INC. (AXSM) reported Increase (Decrease) in Accounts Receivable of $52.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $26.40M, a 29.47% decline year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $26.60M, a 37.13% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $27.96M, a 56.14% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$2.32M, a 161.75% decline year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $82.46M, a 74.78% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $47.18M, a 17.40% decline from fiscal 2023.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $57.12M, a 51.52% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $37.70M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $52.99M 10-Q · filed 2026-08-10 | $80.95M derived: sum of 3 quarters · filed 2026-08-10 | $78.63M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $26.60M 10-Q · filed 2026-05-04 | $54.55M derived: sum of 2 quarters · filed 2026-05-04 | $52.24M derived: sum of 3 quarters · filed 2026-05-04 | $89.67M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $27.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $25.64M derived: sum of 2 quarters · filed 2026-02-23 | $63.07M derived: sum of 3 quarters · filed 2026-08-10 | $82.46M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $35.11M derived: sum of 2 quarters · filed 2026-08-10 | $54.51M 10-Q · filed 2025-11-03 | $72.41M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $37.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $56.82M 10-Q · filed 2026-08-10 | $74.73M derived: sum of 3 quarters · filed 2026-08-10 | $78.48M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $19.40M 10-Q · filed 2026-05-04 | $37.30M derived: sum of 2 quarters · filed 2026-05-04 | $41.05M derived: sum of 3 quarters · filed 2026-05-04 | $59.96M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $21.66M derived: sum of 2 quarters · filed 2026-02-23 | $40.57M derived: sum of 3 quarters · filed 2026-02-23 | $47.18M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $22.66M derived: sum of 2 quarters · filed 2025-11-03 | $29.28M 10-Q · filed 2025-11-03 | $45.68M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $18.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $25.52M 10-Q · filed 2025-08-04 | $41.93M derived: sum of 3 quarters · filed 2026-02-23 | $52.93M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | $6.62M 10-Q · filed 2025-05-05 | $23.02M derived: sum of 2 quarters · filed 2026-02-23 | $34.02M derived: sum of 3 quarters · filed 2026-02-23 | $56.64M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $16.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $27.41M derived: sum of 2 quarters · filed 2026-02-23 | $50.03M derived: sum of 3 quarters · filed 2026-02-23 | $57.12M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $11.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $33.62M derived: sum of 2 quarters · filed 2024-11-12 | $40.72M 10-Q · filed 2024-11-12 | $58.11M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-06-30 | $22.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $29.71M 10-Q · filed 2024-08-05 | $47.11M derived: sum of 3 quarters · filed 2025-02-18 | $51.24M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-03-31 | $7.09M 10-Q · filed 2024-05-06 | $24.49M derived: sum of 2 quarters · filed 2025-02-18 | $28.63M derived: sum of 3 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $21.53M derived: sum of 2 quarters · filed 2025-02-18 | $37.70M 10-K · filed 2025-02-18 | $37.70M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $20.30M 10-Q · filed 2023-11-06 | $20.30M 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | $16.17M 10-Q · filed 2023-08-07 | $16.17M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |